- Argentina
- Australia
- Austria
- Bangladesh
- Belgium
- Botswana
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Cuba
- Czech Republic
- Egypt
- Estonia
- Ethiopia
- Finland
- France
- Germany
- Ghana
- Greece
- Hong Kong
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Kenya
- Latvia
- Lebanon
- Lithuania
- Malaysia
- Mexico
- Morocco
- Namibia
- Netherlands
- New Zealand
- Nigeria
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Romania
- Russia
- Saudi Arabia
- Senegal
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Tanzania
- Thailand
- Turkey
- Uganda
- Ukraine
- United Arab Emirates
- United Kingdom
- United States
- Venezuela
- Vietnam
- Zimbabwe
Pakistan Business News API
Get the live top business headlines from Pakistan with our JSON API.
Get API key for the Pakistan Business News APIAPI Demonstration
This example demonstrates the HTTP request to make and the JSON response you will receive when you use the news api to get the top headlines from Pakistan.
GET
https://gnews.io/api/v4/top-headlines?country=pk&category=business&apikey=API_KEY
{
"totalArticles": 325352,
"articles": [
{
"id": "a55fc42007da696eb3fda9c20bceec59",
"title": "Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Its Recent Share Price Momentum",
"description": "Why Jazz Pharmaceuticals (JAZZ) Is Drawing Investor Attention Jazz Pharmaceuticals (JAZZ) is back on many watchlists after a strong recent run, with the stock up about 18% over the past month and roughly 39% in the past 3 months. See our latest analysis for Jazz Pharmaceuticals. At a share price of $239.83, Jazz Pharmaceuticals has seen momentum build, with a 30 day share price return of 18.5% contributing to a 1 year total shareholder return of 121.9%. If you’re watching Jazz’s recent move...",
"content": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.\nWhy Jazz Pharmaceuticals (JAZZ) Is Drawing Investor Attention\nJazz Pharmaceuticals (JAZZ) is back on many watchlists after a strong rec... [4254 chars]",
"url": "https://finance.yahoo.com/markets/stocks/articles/assessing-jazz-pharmaceuticals-jazz-valuation-002316907.html",
"image": "https://s.yimg.com/os/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
"publishedAt": "2026-05-23T00:23:00Z",
"lang": "en",
"source": {
"id": "70a82950f0d66a71e23738bed9b784cc",
"name": "Yahoo Finance",
"url": "https://finance.yahoo.com"
}
},
{
"id": "474d4521dcd93913f17384ab77cb8f0e",
"title": "What Does the Demand for Natural Gas and LNG Look Like for the Next 20 Years?",
"description": "AI’s Power Hunger, LNG Export Ambitions, and Whether America Can Keep Energy AffordableThe United States stands at a pivotal moment in its energy story. President Trump has signaled aggressive plans to double U.S. LNG exports in roughly 3.5 years, while artificial intelligence data centers are driving explosive growth in electricity demand that natural gas is poised to",
"content": "AI’s Power Hunger, LNG Export Ambitions, and Whether America Can Keep Energy Affordable\nThe United States stands at a pivotal moment in its energy story. President Trump has signaled aggressive plans to double U.S. LNG exports in roughly 3.5 years, w... [7684 chars]",
"url": "https://energynewsbeat.co/ai/what-does-the-demand-for-natural-gas-and-lng-look-like-for-the-next-20-years/",
"image": "https://energynewsbeat.co/wp-content/uploads/2026/05/US-Natural-Gas-and-LNG-Exports-by-Grok.jpg",
"publishedAt": "2026-05-23T00:00:00Z",
"lang": "en",
"source": {
"id": "2548dbc7f7aeefb990c24830128b33c2",
"name": "Energy News Beat",
"url": "https://energynewsbeat.co"
}
},
{
"id": "8ae9f445d7e8ac151af55df969de4f85",
"title": "Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience",
"description": "New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate canc...",
"content": "New analyses from the multicenter phase III CAPItello-281 trial of the AKT1/2/3 inhibitor capivasertib plus the CYP17-inhibitor abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer—now sometimes described as androgen pathway mod... [9684 chars]",
"url": "https://ascopost.com/issues/may-25-2026/adding-capivasertib-to-abiraterone-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-the-patient-experience/",
"image": "https://ascopost.com/media/14026993/george_daniel-j.jpg",
"publishedAt": "2026-05-22T21:19:59Z",
"lang": "en",
"source": {
"id": "5401c1d9e8abd37eaccdf84494dc5ed8",
"name": "The ASCO Post",
"url": "https://ascopost.com"
}
}
]
}